

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 6-K**

**REPORT OF FOREIGN ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16  
OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report: October 23, 2023**

**(Commission File No. 001-39308)**

**CALLIDITAS THERAPEUTICS AB**

**(Translation of registrant's name into English)**

**Kungsbron 1, D5**

**SE-111 22**

**Stockholm, Sweden**

**(Address of registrant's principal executive office)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

---

---

## INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

Enclosed hereto is a copy of an announcement published by Calliditas Therapeutics AB on October 23, 2023.

The information contained in this Form 6-K, including Exhibit 99.1, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

### EXHIBIT INDEX

<b>Exhibit</b>	<b>Description</b>
<a href="#">99.1</a>	<a href="#">Press Release dated October 23, 2023</a>

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**CALLIDITAS THERAPEUTICS AB**

Date: October 23, 2023

By: /s/ Fredrik Johansson

Fredrik Johansson

Chief Financial Officer

---



Stockholm, Sweden

October 23, 2023

## **Calliditas Therapeutics' nomination committee composition for the AGM 2024**

**It is hereby announced that Calliditas Therapeutics' major owners have appointed a nomination committee for the AGM 2024.**

The nomination committee, which is appointed in accordance with the principles adopted by the extraordinary general meeting in 2017, consists of:

- Patrick Sobocki, appointed by Stiftelsen Industrifonden
- Karl Tobieson, appointed by Linc AB
- Spike Loy, appointed by BVF
- Elmar Schnee (chairman of the board of directors)

The nomination committee shall, before the annual general meeting 2024, prepare a proposal for the election of chairman and other members of the board of directors, the election of chairman of the annual meeting, election of auditors, the determination of fees and matters pertaining thereto.

For more information please visit:

<https://www.calliditas.se/en/nomination-committee-2314/>

Shareholders who wish to submit proposals to the nomination committee for the annual general meeting 2024, can do so by e-mail to [finance@calliditas.com](mailto:finance@calliditas.com). Proposals should be submitted to the nomination committee before March 15, 2024.

**For further information, please contact:**

Fredrik Johansson, CFO at Calliditas  
E-mail: [fredrik.johansson@calliditas.com](mailto:fredrik.johansson@calliditas.com)  
Telephone: +46 703 52 91 90

*The information was submitted for publication, through the agency of the contact person set out above, at 3:00 p.m CET on October 23, 2023.*

### **About Calliditas Therapeutics**

Calliditas Therapeutics is a commercial stage biopharma company based in Stockholm, Sweden focused on identifying, developing, and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs. Calliditas' lead product, developed under the name Nefecon, has been granted accelerated approval by the FDA under the trade name TARPEYO® and conditional marketing authorization by the European Commission under the trade name Kinpeygo®. Kinpeygo is being commercialized in the European Union Member States by Calliditas' partner, STADA Arzneimittel AG. Additionally, Calliditas is conducting a Phase 2b clinical trial in primary biliary cholangitis and a Phase 2 proof-of-concept trial in head and neck cancer with its NOX inhibitor product candidate, setanaxib. Calliditas' common shares are listed on Nasdaq Stockholm (ticker: CALTX) and its American Depositary Shares are listed on the Nasdaq Global Select Market (ticker: CALT).

---